184 related articles for article (PubMed ID: 11239520)
1. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients.
Pillans PI; Rigby RJ; Kubler P; Willis C; Salm P; Tett SE; Taylor PJ
Clin Biochem; 2001 Feb; 34(1):77-81. PubMed ID: 11239520
[TBL] [Abstract][Full Text] [Related]
2. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
5. RELATE: Relationship of limited sampling strategy and adverse effects of mycophenolate mofetil in pediatric renal transplant patients.
Berger I; Haubrich K; Ensom MHH; Carr R
Pediatr Transplant; 2019 Mar; 23(2):e13355. PubMed ID: 30689262
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
[TBL] [Abstract][Full Text] [Related]
7. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
Kuypers DR; Ekberg H; Grinyó J; Nashan B; Vincenti F; Snell P; Mamelok RD; Bouw RM
Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolic acid concentrations are associated with cardiac allograft rejection.
DeNofrio D; Loh E; Kao A; Korecka M; Pickering FW; Craig KA; Shaw LM
J Heart Lung Transplant; 2000 Nov; 19(11):1071-6. PubMed ID: 11077224
[TBL] [Abstract][Full Text] [Related]
10. [Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients].
Kuriata-Kordek M; Boratyńska M; Urbaniak J; Woźniak M; Patrzałek D; Szyber P; Klinger M
Pol Merkur Lekarski; 2006 Aug; 21(122):161-3; discussion 164. PubMed ID: 17144102
[TBL] [Abstract][Full Text] [Related]
11. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M
Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
[TBL] [Abstract][Full Text] [Related]
14. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.
Weber LT; Shipkova M; Armstrong VW; Wagner N; Schütz E; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B
Clin Chem; 2002 Mar; 48(3):517-25. PubMed ID: 11861442
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
[TBL] [Abstract][Full Text] [Related]
18. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.
Shaw LM; Korecka M; DeNofrio D; Brayman KL
Clin Biochem; 2001 Feb; 34(1):17-22. PubMed ID: 11239510
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
Weber LT; Armstrong VW; Shipkova M; Feneberg R; Wiesel M; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B;
Ther Drug Monit; 2004 Aug; 26(4):415-24. PubMed ID: 15257072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
